Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Coleman, RE
  • Rosen, LS
  • Gordon, D
  • Major, Pierre
  • Kaminski, M
  • Apffelstaedt, J
  • Howell, A
  • Chen, BL
  • Seaman, JJ

publication date

  • December 1, 2002